Next Article in Journal
Isolation and Molecular Characterization of Atypical Porcine Pestivirus Emerging in China
Next Article in Special Issue
COVID-19 Pharmacotherapy: A Summary of Key Advances and Insights from the Special Issue
Previous Article in Journal
Pteropus vampyrus TRIM40 Is an Interferon-Stimulated Gene That Antagonizes RIG-I-like Receptors
Previous Article in Special Issue
Phenothiazines Inhibit SARS-CoV-2 Entry through Targeting Spike Protein
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Viruses
Volume 15
Issue 11
10.3390/v15112148
viruses-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Immune-Cell-Based Therapy for COVID-19: Current Status

by
Yiyuan Wang
1,2,3,†,
Qinghe Liang
1,2,3,†,
Fengsheng Chen
1,2,3,†,
Jiehuang Zheng
1,2,3,
Yan Chen
1,2,3,
Ziye Chen
1,2,3,
Ruopeng Li
1,2,3 and
Xiaojuan Li
1,2,3,*
1
Laboratory of Anti-Inflammatory and Immunomodulatory Pharmacology, Innovation Program of Drug Research on Inflammatory and Immune Diseases, Southern Medical University, Guangzhou 510515, China
2
NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
3
Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Viruses 2023, 15(11), 2148; https://doi.org/10.3390/v15112148
Submission received: 19 August 2023 / Revised: 27 September 2023 / Accepted: 27 September 2023 / Published: 25 October 2023
(This article belongs to the Special Issue COVID-19 Pharmacotherapy)
Browse Figures
Versions Notes

Abstract

:
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. The interplay between innate and adaptive immune responses plays a crucial role in managing COVID-19. Cell therapy has recently emerged as a promising strategy to modulate the immune system, offering immense potential for the treatment of COVID-19 due to its customizability and regenerative capabilities. This review provides an overview of the various subsets of immune cell subsets implicated in the pathogenesis of COVID-19 and a comprehensive summary of the current status of immune cell therapy in COVID-19 treatment.

1. Introduction

The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had a devastating impact worldwide for over four years. This novel infectious disease has resulted in millions of fatalities, with the death tolls continuing to rise due to the emergence of new variants [1]. COVID-19 presents with respiratory symptoms associated with viral replication, along with systemic effects, making it a complex illness [2]. Common symptoms include fever, cough, and respiratory distress, with severe cases progressing to respiratory failure and even death [3].
The pathophysiology of COVID-19 is primarily characterized by dysregulated immune responses against SARS-CoV-2, involving both innate and adaptive immune components [4]. This dysregulation not only hinders viral clearance but also leads to inflammation, tissue damage in the lungs, and multi-organ damage systemically [5]. Various immune cells, including T cells, natural killer (NK) cells, dendritic cells (DCs), and macrophages, play crucial roles in SARS-CoV-2 infections [6]. Hence, immunotherapy targeting these immune cells presents a promising avenue for mitigating the pathology of SARS-CoV-2 infection, preventing long-term complications, and improving overall survival rates in infectious diseases.
Cellular therapy, an innovative approach to disease treatment, involves the utilization of specialized cells with specific functions obtained through bioengineering and ex vivo expansion, followed by reinfusion into the patient’s body [7]. Chimeric antigen receptor (CAR) T-cell therapy, which has gained approval from the US Food and Drug Administration, has demonstrated significant advancements in the treatment of B-cell malignancies [8]. Immune-cell-based therapies offer distinct advantages over conventional treatments, including high selectivity, localized concentration, and personalization [9]. Over the past decade, cancer immunotherapy has witnessed remarkable success, establishing immune cell therapy as a transformative treatment modality for various diseases, including COVID-19.
In the context of COVID-19, immune cell therapy is a promising approach for effective treatment. This review provides an overview of the different immune cell subsets involved in the pathogenesis of COVID-19 and summarizes the progress in immune cell therapy research and clinical trials targeting COVID-19 (Table 1).

2. T Cell Therapy

T lymphocytes, derived from lymphoid stem cells in the bone marrow, undergo differentiation and maturation in the thymus. They then circulate through the lymph and blood, playing a critical role in cellular immunity throughout various immune organs and tissues in the body. Pathological excessive inflammation, associated with lymphocyte reduction and dysregulated T cell responses, is one of the immunological characteristics of COVID-19 [10]. The success of T cell therapy in treating life-threatening viral infections supports its potential application in COVID-19 treatment [11].

2.1. Specific T Cell Therapy in COVID-19

Specific T cell therapy involves isolating and expanding virus-specific T cells that can recognize the structural proteins of SARS-CoV-2, particularly the membrane protein (Figure 1a). Notably, blood from donors exposed to SARS-CoV-2 contains memory CD4 and CD8+ T cells capable of recognizing various viral antigens, including spike proteins, nucleocapsid proteins, and membrane antigens [12]. Cultivating SARS-CoV-2-specific T cells in the presence of interleukin (IL)-2/4/7 can increase their proliferation by over 1000 times while preserving their phenotype, function, and antigen recognition hierarchy compared to baseline samples [13]. This approach allows for the generation of expanded cytotoxic T lymphocytes (CTLs) targeting the structural proteins of SARS-CoV-2, including the receptor-binding domain of the spike protein [13]. Incorporating HLA-E-restricted CD8 T cells into T cell immunotherapy for COVID-19 offers several advantages, including the ability to eliminate infected cells, inhibit intracellular infection, reduce inflammatory reactions, and limit tissue damage, which are important mechanisms in the pathogenesis of COVID-19 [14].
In vitro experiments have demonstrated that clinically relevant levels of SARS-CoV-2-specific T cells maintain their functionality and proliferative capacity while retaining their specific cytotoxic potential. These T cells exhibit functional and phenotypic stability within days after enrichment [15]. In vitro expansion and isolation of SARS-CoV-2-specific T cells producing IFNγ have been successfully achieved, showing peptide-specific cytolytic and proliferative responses upon re-exposure to the antigen [16]. Furthermore, in vitro expanded SARS-CoV-2 antigen-specific T cells using partially HLA-matched third-party products have shown potential in the treatment of severe cases of COVID-19 unresponsive to previous interventions [17]. Currently, a phase I clinical trial is underway to assess the safety and feasibility of immunotherapy with infused CD45RA memory T cells, including SARS-CoV-2-specific T cells, for the treatment of moderate to severe COVID-19 cases [18]. Additionally, a randomized (2:1), open-label phase I/II trial is evaluating the safety and efficacy of pre-made, partially human leukocyte antigen (HLA)-matched SARS-CoV-2-specific T cells from recovered patients (CoV-2-STs) in combination with standard-of-care therapy (SoC) for the treatment of severe COVID-19 patients [19]. Numerous clinical trials investigating specific T cell therapies for COVID-19 are currently underway (Table 1).

2.2. CAR-T Cell Therapy in COVID-19

CAR-T cells, which are engineered T cells with the ability to specifically recognize and attack tumor cells, have emerged as a promising approach for combating COVID-19. These CAR-T cells are designed to target SARS-CoV-2 viral antigens, particularly the N protein(Figure 1b). Mathematical models have been developed to describe the dynamics of infection involving the virus, CAR-T cells, and memory cells. Theoretical analysis suggests that this approach can generate positive therapeutic effects by delaying viral production, which is particularly beneficial in the early stages of infection. This study highlights the potential use of CAR-T cells as an antiviral therapy for COVID-19 [20].

3. Tregs Therapy

Regulatory T cells (Tregs) are a group of immune-suppressive cells that play a crucial role in maintaining immune homeostasis and preventing autoimmune reactions [21,22]. Some studies have indicated a decrease in the number of Tregs in the peripheral blood of COVID-19 patients [23,24,25,26]. Mahmoud et al. evaluated the frequencies of Tregs and Th17 cells in healthy individuals and COVID-19 patients using flow cytometry. The results showed a significant decrease in the frequency of Tregs and an increase in the frequency of Th17 cells and the Th17/Treg ratio, particularly in severe COVID-19 patients. Moreover, the expression levels of ROR-γt and FoxP3 were found to increase and decrease, respectively, as the disease progressed [24]. Another study demonstrated that non-survivor patients had lower levels of Tregs and lower FOXP3 expression compared to survivors. However, conflicting results regarding changes in Treg levels in COVID-19 patients have also been reported. Some studies have shown a significant increase in the frequency of CD25+CD127-Foxp3+ Tregs in critically ill COVID-19 patients [27,28].
However, Tregs play a crucial role in suppressing the activation, proliferation, and effector functions of other immune cells, and they are involved in inhibiting self-immune inflammatory reactions. Tregs may exert a protective effect on COVID-19 patients with excessive inflammation and cytokine storms [29,30]. Based on the anti-inflammatory characteristics of Tregs, Treg-based immunotherapy may provide a viable option for treating COVID-19 (Figure 1c). This viewpoint is supported by a recent case study that examined the effects of Treg transplantation from umbilical cord blood. Two patients with acute respiratory distress syndrome received two to three different allogeneic umbilical-cord-blood-derived Tregs that were expanded in vitro, resulting in a significant reduction in the production of inflammatory mediators and achieving good efficacy. Further clinical trials are being conducted to explore the use of umbilical-cord-blood-derived Tregs for the treatment of COVID-19-related acute respiratory distress syndrome (ARDS) (Table 1) [31]. Additionally, Harb et al. found that increased expression of Notch4 in circulating Tregs is associated with disease severity and can predict mortality, with decreased expression observed after recovery. Increased Notch expression can restrict Treg-mediated tissue repair and promote severe lung inflammation during viral infections [32]. Inhibiting Notch expression may be a potential approach for treating COVID-19. Currently, there are four clinical trials for Treg cell therapy in COVID-19, including two completed and two terminated (Table 1).

4. NK Cell Therapy

NK cells, also known as natural killer cells, are a type of large granular lymphocyte belonging to the innate immune system. They constitute approximately 5–20% of the total lymphocyte population in the human body [33]. NK cells originate from lymphoid progenitor cells and undergo maturation at various locations, such as the bone marrow, thymus, and spleen, before entering the bloodstream [34]. In response to viral infection, NK cells can directly or indirectly eliminate virus-infected cells through the release of perforin and granzymes or by exerting antibody-dependent cellular cytotoxicity (ADCC) [35]. Cytokines like IL-2, IL-12, and IL-15 can induce NK cells to secrete pro-inflammatory cytokines, such as TNF-α and IFN-γ, activating other immune responses to control viral infections [36]. Notably, COVID-19 patients often experience a significant decrease in NK cell numbers [37].
Building upon the understanding of NK cell biology, many researchers have utilized NK cell therapy to treat viral infections caused by key human pathogens, including SADS, influenza, and the SARS-CoV-2 virus [38,39,40]. NK cell therapy has demonstrated promising results in the treatment of COVID-19 infection in animal studies. Lu et al. developed mACE2-CAR, a fusion protein combining a mutated fragment of ACE2 (mACE2) with intracellular signaling domains CD28 and CD3ζ, and incorporated it into NK cells isolated from umbilical cord blood, resulting in mACE2-CAR-sIL15 NK cells. The study revealed that these NK cells exhibited strong protective effects against SARS-CoV-2 infection in K18-hACE2 mice, a transgenic mouse model expressing human ACE2 in respiratory epithelial cells [41].
NK cell therapy for the treatment of COVID-19 has progressed to the clinical trial stage (Table 1). CAR-NK cells, derived from umbilical cord blood, have been genetically engineered to target two specific molecules, MKG2D and ACE2. By binding to these molecules, CAR-NK cells can prevent SARS-CoV-2 viral infection of ACE2-expressing host cells and enhance the cytotoxicity of CAR-NK cells, enabling rapid elimination of virus-infected cells [42]. Liu et al. constructed and prepared universal IL15 super-antagonist and GM-CSF neutralizing scFv-secretory NKG2D-ACE2 CAR-NK cells from umbilical cord blood. These CAR-NK cells target the S protein of SARS-CoV-2 and NKG2DL on the surface of infected cells while also providing a preventive effect against cytokine release syndrome (CRS) through IL15 super-antagonist and GM-CSF neutralizing scFv. This approach facilitates viral particle clearance. Furthermore, ACE2 CAR-NK cells can competitively inhibit SARS-CoV-2 infection of type II alveolar epithelial cells and other vital organs or tissues, effectively terminating the SARS-CoV-2 infection. That study is currently in phase 1/2 of clinical trials [43]. Another approach, known as CYNK-001 therapy, utilizes non-genetically-modified natural killer (NK) cells derived from cryopreserved human placental hematopoietic stem cells. CYNK-001 cells are obtained by expanding and differentiating placental hematopoietic stem/progenitor CD34+ cells through a 35-day culture process [44]. CYNK-001 cells express NKG2D and CD94, as well as NK activation receptors DNAM1, NKp30, NKp46, and NKp44. In preclinical studies, CYNK-001 has demonstrated a range of biological activities expected from NK cells, including perforin and granzyme B expression. Currently, CYNK-001 is undergoing phase 1/2 clinical trials for the treatment of COVID-19 infection [45].

5. DC Cell Therapy

Dendritic cell (DC) therapy has emerged as a promising approach in the field of immunotherapy. DCs are considered the most effective antigen-presenting cells and play crucial roles in both innate and adaptive immunity, as well as in the induction of immune tolerance [46]. When exposed to viruses, DCs undergo stimulation and differentiate into two distinct types. Uninfected DCs exert antiviral immune functions, while infected DCs participate in immune evasion processes [47]. SARS-CoV-2 has the ability to infect DCs, and studies have shown that this infection can lead to a decrease in the number and function of DCs, resulting in acute immune dysfunction [48]. This immune dysfunction contributes to the immune evasion of SARS-CoV-2.
Current research has identified various mechanisms through which SARS-CoV-2 can invade host cells, including binding with angiotensin-converting enzyme 2 (ACE2), interacting with DC-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN), interacting with CD147, and interacting with the dipeptidyl peptidase-4 (DPP4) receptor [49,50]. DC-SIGN and CD147 are expressed on DCs, while ACE2 is expressed on pulmonary interstitial DCs. Studies suggest that SARS-CoV-2 can replicate within DCs, although DCs do not transmit the newly generated virus, indicating the ability of SARS-CoV-2 to infect DCs. Clinical data further indicate a decrease in the proportion of conventional DCs (cDCs) and plasmacytoid DCs (pDCs) during the acute and recovery phases of the disease [48], as well as a reduction in the expression of IFN-α, IFN-β [51,52], and co-stimulatory molecules. The impaired and disrupted function of DCs hampers innate and adaptive immune responses, aiding in the viral escape from the host’s immune mechanisms [53].
Currently, COVID-19 vaccine development primarily focuses on viral vectors, nucleic acids (RNA), protein subunits, and inactivated or killed viruses. However, DCs have emerged as potential candidates for vaccine development, as they can process antigens and present them to immune cells. Clinical trials are currently underway to explore the application of DCs in generating COVID-19 vaccines (Table 1). Strategies for vaccine preparation based on DCs include the adoption of chimeric antigen receptor (CAR) strategies, in vitro loading of autologous DCs with SARS-CoV-2 S protein, combining DCs with nanotechnology, and targeting vaccine antigens to DCs through surface receptors, among others [54]. Currently, there are a limited number of vaccines based on DC or DC-enhancing strategies, as well as nanoparticle (NP)-based vaccines to enhance DC function against SARS-CoV-2, with approximately five in total. The highest clinical stage reached is phase III [55]. Developing vaccines that target the role of DCs in immunity offers unique advantages due to the pivotal role of DCs in innate and adaptive immunity, as well as their susceptibility during infection. Vaccination targeting DCs has the potential to address defects in innate and adaptive immune responses, leading to improved outcomes and contributing to long-term and widespread immunity.

6. Monocyte–Macrophage Cell Therapy

The monocyte–macrophage system consists of monocytes in the bloodstream and tissue-resident macrophages [56]. In the lung tissue of mild COVID-19 patients, the number of monocyte–macrophages is low [57]. However, in severe COVID-19 patients, the infection of alveolar epithelial cells by SARS-CoV-2 induces the production of chemokine CCL2, which attracts a large number of circulating monocytes and tissue-resident alveolar macrophages to the site of infection [58]. Once in the tissue, monocytes enhance their phagocytic capacity and gradually differentiate into macrophages, which further secrete pro-inflammatory cytokines (IL-6, IL-7, TNF, etc.) and chemokines (CCL2, CCL3, CCL7, CCL10, etc.), mediating immune responses and engulfing pathogens [59]. It is noteworthy that the substantial amount of cytokines produced by these macrophages in the lung tissue of severe patients can promote pulmonary fibrosis, which is a significant cause of death in COVID-19 patients [60].
Although monocyte–macrophages have long been implicated in promoting tissue fibrosis, due to the plasticity of monocyte–macrophages’ function, recent studies have shown that they also play a pivotal role in fibrosis regression, in part through the expression of matrix-degrading metalloproteinase enzymes (MMPs) [61]. Thus, increasing anti-fibrotic monocyte/macrophage populations is important for clearing partially degraded collagen fragments of the extracellular matrix, especially fibrillar collagen. An attractive therapeutic strategy would be the use of monocytes modified in vitro as a cell therapy to induce fibrosis regression. MON002 is an autologous monocyte cell product that undergoes ex vivo culture before being intravenously injected into patients with post-COVID-19 pulmonary fibrosis [20]. The MONACO Cell Therapy Study is a prospective, non-randomized, open-label phase I/II clinical trial aimed at evaluating the safety of MON002 in five adult patients diagnosed with interstitial lung disease (pulmonary fibrosis) recovering from acute COVID-19 infection (Table 1).

7. MSC Therapy

Mesenchymal stem cells (MSCs) are a type of adult stem cell that originate from the mesoderm and have the potential for self-renewal and multidirectional differentiation. They can differentiate into various mesenchymal tissues, such as bone, cartilage, adipose tissue, and bone marrow hematopoietic tissue. During the process of COVID-19 infection, MSCs reduce cytokine storms, limit organ inflammation and fibrotic damage, and regulate innate and adaptive immune responses through the release of bioactive molecules and direct cell–cell contact. Additionally, MSCs can modulate the clearance of alveolar fluid and the permeability of pulmonary endothelial cells, thereby improving lung injury and associated inflammatory reactions. It is worth noting that most MSCs do not express the ACE2 receptor, and, after intravenous injection, MSCs are distributed predominantly in the pulmonary microvasculature, enhancing the persistence of their effects through this unique immune evasion mechanism, making them potential candidates for COVID-19 treatment [62,63]. The safety of MSC-based therapeutic approaches has been confirmed in various clinical trials conducted over the past few decades, and multiple products have been approved for different diseases [64].
Animal studies have shown that MSCs can improve lung function in acute lung injury (ALI) mouse models and reduce the secretion of inflammatory cytokines [65]. Furthermore, preliminary observational studies suggest that MSCs may provide therapeutic benefits in COVID-19-related acute respiratory distress syndrome (ARDS) [66,67]. In severe or critical cases of COVID-19, ARDS remains a highly fatal condition that can result in pulmonary edema, arterial hypoxemia, and impaired lung function [68]. Unfortunately, treatment options for ARDS are still limited. However, many ongoing clinical trials involving over 1600 subjects have found the safety and efficacy of using MSCs in the treatment of severe COVID-19 cases [69,70,71,72,73,74,75,76,77].
Leng et al. found that treatment with an intravenous infusion of 1 × 106 umbilical cord mesenchymal stem cells (UC-MSCs)/kg for 14 days reduced inflammation and promoted lung tissue regeneration [76,78]. Sadeghi et al. found that MSC therapy improved oxygenation, cleared lung infiltrates, and reduced peripheral blood levels of inflammatory cytokines, with 80% of patients recovering and leaving the ICU within a median of 6 days after receiving one to two doses of intravenous MSCs [79]. Similar findings were reported by Lanzoni et al. [70,77]. In addition, a phase 2 clinical trial with a large number of patients showed that UC-MSC therapy significantly improved lung lesion volume on day 28. Data collected every 3 months by Shi et al. showed continued improvement in lung lesions at the 3-month mark in patients treated with UC-MSCs [72,73].
Clinical trial results have revealed that the use of MSCs for treating COVID-19 patients is not an unrealistic therapeutic approach. Furthermore, the use of MSC-based therapy is considered a suitable treatment option for severely ill COVID-19 patients [77,80,81]. However, further research is needed to evaluate the safety, efficacy, and long-term outcomes of using different types of MSCs [82]. Although clinical studies related to MSCs are still in their early stages, MSCs hold great promise as clinical tools for the future.

8. Discussion

Over the past years, immune cell therapy for cancer has continued to be enthusiastic, showing the great potential of immune cells for the treatment of human diseases. COVID-19 invasion has caused the concept of immune cell therapy to become highly popular once again. Several articles have focused on this field [83,84]. In this article, we summarized the types of cell therapies currently in the clinical trial stage (Figure 2) and listed the latest representative clinical trial programs for COVID-19 immune cell therapy (Table 1).
However, COVID-19 immune cell therapy is still in the early stages of development, and the key to its development will be the availability of high-quality immune cells and a standardized cell preparation process. The first key point is the high quality of immune cells. Research has confirmed that viral infections can lead to a decrease in the number of immune cells in the body, and even lead to a decline in cellular immune function [5]. Therefore, in order to carry out immune cell therapy, first, it is necessary to guarantee a sufficient number of these immune cells, especially for those therapies aimed at treating solid tissue diseases. Both cell migration and localization to the target site are important considerations, and these may depend heavily on the initial delivery route. Currently, other alternatives to intravenous administration are being investigated, including intradermal, intra-lymph node, subcutaneous, and others. These may provide solutions to this long-standing biological challenge. Secondly, it is important to ensure that these immune cells are of high quality. The efficacy of cell therapy depends heavily on the ability of the cells to maintain their functionality in vivo. Processes of in vitro cell pre-treatment, such as freezing and thawing, may have an impact on the function of the cells [85]. And, changes in the function of the living cells, such as depletion and lack of persistence, can occur after administration of the drug. The solutions to these challenges are often complex. It can be achieved through genetic modification methods, but also through pretreatment with cytokines, small molecules, hypoxia, and/or biomaterials in order to adjust their function to the desired application. The second key point is to have a standardized immune cell preparation process or production process. The development of closed automated production processes is a necessary and challenging task to produce safe, high-quality cell therapy products. Current areas of focus include manufacturing processes for cryopreservation, cell selection and cell activation, as well as automated batch monitoring for quality assurance purposes and the adoption of electronic recording systems. These interventions have the potential to reduce the heterogeneity of cell therapies and shorten production times. In the future, decentralized manufacturing processes will scale up the global availability of cell therapies, making them accessible to patients who are currently hard to reach.
Another avenue to consider for future immune cell therapy in COVID-19 is the use of a combination of immune cell therapies. For example, the synergistic effects of MSCs with other cell types, including lung endothelial cells and epithelial cells, have been studied [86]. These findings support the investigation of these two cell types as combination cell therapies.
Immune cell therapy is considered a highly active area of research because of the current positive clinical advances, and it is expected that more disruptive cell therapy products for the treatment of viral infections, such as COVID-19, will emerge in the near future.

Author Contributions

Conceptualization, Y.W. and X.L.; data curation, F.C.; writing—original draft preparation, J.Z., Y.C., Z.C. and R.L.; writing—review and editing, Y.W., Q.L. and X.L.; visualization, Q.L.; supervision, X.L.; project administration, X.L.; funding acquisition, X.L. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (82173825, 81973335).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Carabelli, A.M.; Peacock, T.P.; Thorne, L.G.; Harvey, W.T.; Hughes, J.; Peacock, S.J.; Barclay, W.S.; de Silva, T.I.; Towers, G.J.; Robertson, D.L.; et al. SARS-CoV-2 variant biology: Immune escape, transmission and fitness. Nat. Rev. Microbiol. 2023, 21, 162–177. [Google Scholar]
  2. Markov, P.V.; Ghafari, M.; Beer, M.; Lythgoe, K.; Simmonds, P.; Stilianakis, N.I.; Katzourakis, A. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 2023, 21, 361–379. [Google Scholar]
  3. Singh, S.J.; Baldwin, M.M.; Daynes, E.; Evans, R.A.; Greening, N.J.; Jenkins, R.G.; Lone, N.I.; McAuley, H.; Mehta, P.; Newman, J.; et al. Respiratory sequelae of COVID-19: Pulmonary and extrapulmonary origins, and approaches to clinical care and rehabilitation. Lancet Respir. Med. 2023, 11, 709–725. [Google Scholar]
  4. Koutsakos, M.; Ellebedy, A.H. Immunological imprinting: Understanding COVID-19. Immunity 2023, 56, 909–913. [Google Scholar] [CrossRef]
  5. Altmann, D.M.; Whettlock, E.M.; Liu, S.; Arachchillage, D.J.; Boyton, R.J. The immunology of long COVID. Nat. Rev. Immunol. 2023. ahead of print. [Google Scholar]
  6. Merad, M.; Blish, C.A.; Sallusto, F.; Iwasaki, A. The immunology and immunopathology of COVID-19. Science 2022, 375, 1122–1127. [Google Scholar] [CrossRef]
  7. Finck, A.V.; Blanchard, T.; Roselle, C.P.; Golinelli, G.; June, C.H. Engineered cellular immunotherapies in cancer and beyond. Nat. Med. 2022, 28, 678–689. [Google Scholar]
  8. Labanieh, L.; Mackall, C.L. CAR immune cells: Design principles, resistance and the next generation. Nature 2023, 614, 635–648. [Google Scholar]
  9. Ringquist, R.; Ghoshal, D.; Jain, R.; Roy, K. Understanding and improving cellular immunotherapies against cancer: From cell-manufacturing to tumor-immune models. Adv. Drug Deliv. Rev. 2021, 179, 114003. [Google Scholar]
  10. Li, C.K.; Wu, H.; Yan, H.; Ma, S.; Wang, L.; Zhang, M.; Tang, X.; Temperton, N.J.; Weiss, R.A.; Brenchley, J.M.; et al. T cell responses to whole SARS coronavirus in humans. J. Immunol. 2008, 181, 5490–5500. [Google Scholar] [CrossRef]
  11. Keller, M.D.; Harris, K.M.; Jensen-Wachspress, M.A.; Kankate, V.V.; Lang, H.; Lazarski, C.A.; Durkee-Shock, J.; Lee, P.H.; Chaudhry, K.; Webber, K.; et al. SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein. Blood 2020, 136, 2905–2917. [Google Scholar] [CrossRef]
  12. Cooper, R.S.; Fraser, A.R.; Smith, L.; Burgoyne, P.; Imlach, S.N.; Jarvis, L.M.; Turner, D.M.; Zahra, S.; Turner, M.L.; Campbell, J.D.M. Rapid GMP-Compliant Expansion of SARS-CoV-2-Specific T Cells from Convalescent Donors for Use as an Allogeneic Cell Therapy for COVID-19. Front. Immunol. 2021, 11, 598402. [Google Scholar] [CrossRef]
  13. Basar, R.; Uprety, N.; Ensley, E.; Daher, M.; Klein, K.; Martinez, F.; Aung, F.; Shanley, M.; Hu, B.; Gokdemir, E.; et al. Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy. Cell Rep. 2021, 20, 109432. [Google Scholar] [CrossRef]
  14. Caccamo, N.; Sullivan, L.C.; Brooks, A.G.; Dieli, F. Harnessing HLA-E-restricted CD8 T lymphocytes for adoptive cell therapy of patients with severe COVID-19. Br. J. Haematol. 2020, 190, e185–e187. [Google Scholar] [CrossRef]
  15. Bonifacius, A.; Tischer-Zimmermann, S.; Santamorena, M.M.; Mausberg, P.; Schenk, J.; Koch, S.; Barnstorf-Brandes, J.; Gödecke, N.; Martens, J.; Goudeva, L.; et al. Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy. Front. Bioeng. Biotechnol. 2022, 10, 867042. [Google Scholar] [CrossRef] [PubMed]
  16. Gil-Bescós, R.; Ostiz, A.; Zalba, S.; Tamayo, I.; Bandrés, E.; Rojas-de-Miguel, E.; Redondo, M.; Zabalza, A.; Ramírez, N. Potency assessment of IFNγ-producing SARS-CoV-2-specific T cells from COVID-19 convalescent subjects. Life Sci. Alliance 2023, 6, e202201759. [Google Scholar] [CrossRef] [PubMed]
  17. Kim, N.; Lee, J.M.; Oh, E.J.; Jekarl, D.W.; Lee, D.G.; Im, K.I.; Cho, S.G. Off-the-Shelf Partial HLA Matching SARS-CoV-2 Antigen Specific T Cell Therapy: A New Possibility for COVID-19 Treatment. Front. Immunol. 2021, 12, 751869. [Google Scholar] [CrossRef] [PubMed]
  18. Pérez-Martínez, A.; Mora-Rillo, M.; Ferreras, C.; Guerra-García, P.; Pascual-Miguel, B.; Mestre-Durán, C.; Borobia, A.M.; Carcas, A.J.; Queiruga-Parada, J.; García, I.; et al. Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE). EClinicalMedicine 2021, 39, 101086. [Google Scholar] [CrossRef]
  19. Papadopoulou, A.; Karavalakis, G.; Papadopoulou, E.; Xochelli, A.; Bousiou, Z.; Vogiatzoglou, A.; Papayanni, P.G.; Georgakopoulou, A.; Giannaki, M.; Stavridou, F.; et al. SARS-CoV-2-specific T cell therapy for severe COVID-19: A randomized phase 1/2 trial. Nat. Med. 2023. ahead of print. [Google Scholar]
  20. Zavvar, M.; Yahyapoor, A.; Baghdadi, H.; Zargaran, S.; Assadiasl, S.; Abdolmohammadi, K.; Hossein Abooei, A.; Reza Sattarian, M.; JalaliFarahani, M.; Zarei, N.; et al. COVID-19 immunotherapy: Treatment based on the immune cell-mediated approaches. Int. Immunopharmacol. 2022, 107, 108655. [Google Scholar] [CrossRef]
  21. Meckiff, B.J.; Ramírez-Suástegui, C.; Fajardo, V.; Chee, S.J.; Kusnadi, A.; Simon, H.; Eschweiler, S.; Grifoni, A.; Pelosi, E.; Weiskopf, D.; et al. Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4(+) T Cells in COVID-19. Cell 2020, 183, 1340–1353. [Google Scholar] [CrossRef]
  22. Liu, K.; Yang, T.; Peng, X.F.; Lv, S.M.; Ye, X.L.; Zhao, T.S.; Li, J.C.; Shao, Z.J.; Lu, Q.B.; Li, J.Y.; et al. A systematic meta-analysis of immune signatures in patients with COVID-19. Rev. Med. Virol. 2021, 31, e2195. [Google Scholar] [CrossRef]
  23. Gonçalves-Pereira, M.H.; Santiago, L.; Ravetti, C.G.; Vassallo, P.F.; de Andrade, M.V.M.; Vieira, M.S.; de Oliveira, F.d.F.S.; Carobin, N.V.; Li, G.; de Paula Sabino, A.; et al. Dysfunctional phenotype of systemic and pulmonary regulatory T cells associate with lethal COVID-19 cases. Immunology 2023, 168, 684–696. [Google Scholar] [CrossRef] [PubMed]
  24. Mahmoud Salehi Khesht, A.; Karpisheh, V.; Qubais Saeed, B.; Olegovna Zekiy, A.; Yapanto, L.M.; Nabi Afjadi, M.; Aksoun, M.; Nasr Esfahani, M.; Aghakhani, F.; Movahed, M.; et al. Different T cell related immunological profiles in COVID-19 patients compared to healthy controls. Int. Immunopharmacol. 2021, 97, 107828. [Google Scholar] [CrossRef] [PubMed]
  25. Nasrollahi, H.; Talepoor, A.G.; Saleh, Z.; Eshkevar Vakili, M.; Heydarinezhad, P.; Karami, N.; Noroozi, M.; Meri, S.; Kalantar, K. Immune responses in mildly versus critically ill COVID-19 patients. Front. Immunol. 2023, 14, 1077236. [Google Scholar]
  26. Seepathomnarong, P.; Ongarj, J.; Sophonmanee, R.; Seeyankem, B.; Chusri, S.; Surasombatpattana, S.; Pinpathomrat, N. Regulatory T Cells Decreased during Recovery from Mild COVID-19. Viruses 2022, 14, 1688. [Google Scholar] [CrossRef] [PubMed]
  27. Vick, S.C.; Frutoso, M.; Mair, F.; Konecny, A.J.; Greene, E.; Wolf, C.R.; Logue, J.K.; Franko, N.M.; Boonyaratanakornkit, J.; Gottardo, R.; et al. A regulatory T cell signature distinguishes the immune landscape of COVID-19 patients from those with other respiratory infections. Sci. Adv. 2021, 7, eabj0274. [Google Scholar] [CrossRef]
  28. Galván-Peña, S.; Leon, J.; Chowdhary, K.; Michelson, D.A.; Vijaykumar, B.; Yang, L.; Magnuson, A.M.; Chen, F.; Manickas-Hill, Z.; Piechocka-Trocha, A.; et al. Profound Treg perturbations correlate with COVID-19 severity. Proc. Natl. Acad. Sci. USA 2021, 118, e2111315118. [Google Scholar]
  29. Xu, Z.; Jiang, X.; Dai, X.; Li, B. The Dynamic Role of FOXP3(+) Tregs and Their Potential Therapeutic Applications During SARS-CoV-2 Infection. Front. Immunol. 2022, 13, 916411. [Google Scholar]
  30. De Candia, P.; Prattichizzo, F.; Garavelli, S.; Matarese, G. T Cells: Warriors of SARS-CoV-2 Infection. Trends Immunol. 2021, 42, 18–30. [Google Scholar]
  31. Gladstone, D.E.; Kim, B.S.; Mooney, K.; Karaba, A.H.; D’Alessio, F.R. Regulatory T Cells for treating patients with COVID-19 and acute respiratory distress syndrome: Two case reports. Ann. Intern. Med. 2020, 173, 852–853. [Google Scholar] [CrossRef]
  32. Harb, H.; Benamar, M.; Lai, P.S.; Contini, P.; Griffith, J.W.; Crestani, E.; Schmitz-Abe, K.; Chen, Q.; Fong, J.; Marri, L.; et al. Notch4 signaling limits regulatory T-cell-mediated tissue repair and promotes severe lung inflammation in viral infections. Immunity 2021, 54, 1186–1199. [Google Scholar] [CrossRef]
  33. Langers, I.; Renoux, V.M.; Thiry, M.; Delvenne, P.; Jacobs, N. Natural killer cells: Role in local tumor growth and metastasis. Biologics 2012, 6, 73–82. [Google Scholar] [PubMed]
  34. Iannello, A.; Debbeche, O.; Samarani, S.; Ahmad, A. Antiviral NK cell responses in HIV infection: I. NK cell receptor genes as determinants of HIV resistance and progression to AIDS. J. Leukoc. Biol. 2008, 84, 1–26. [Google Scholar] [PubMed]
  35. Biron, C.A.; Nguyen, K.B.; Pien, G.C.; Cousens, L.P.; Salazar-Mather, T.P. Natural killer cells in antiviral defense: Function and regulation by innate cytokines. Annu. Rev. Immunol. 1999, 17, 189–220. [Google Scholar] [CrossRef]
  36. Guidotti, L.G.; Chisari, F.V. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 2001, 19, 65–91. [Google Scholar] [CrossRef] [PubMed]
  37. Zheng, M.; Gao, Y.; Wang, G.; Song, G.; Liu, S.; Sun, D.; Xu, Y.; Tian, Z. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol. Immunol. 2020, 17, 533–535. [Google Scholar] [CrossRef] [PubMed]
  38. Manickam, C.; Shah, S.V.; Nohara, J.; Ferrari, G.; Reeves, R.K. Monkeying Around: Using Non-human Primate Models to Study NK Cell Biology in HIV Infections. Front. Immunol. 2019, 10, 1124. [Google Scholar]
  39. Jegaskanda, S.; Vanderven, H.A.; Tan, H.X.; Alcantara, S.; Wragg, K.M.; Parsons, M.S.; Chung, A.W.; Juno, J.A.; Kent, S.J. Influenza Virus Infection Enhances Antibody-Mediated NK Cell Functions via Type I Interferon-Dependent Pathways. J. Virol. 2019, 93, e02090-18. [Google Scholar] [CrossRef]
  40. Ghasemzadeh, M.; Ghasemzadeh, A.; Hosseini, E. Exhausted NK cells and cytokine storms in COVID-19: Whether NK cell therapy could be a therapeutic choice. Hum. Immunol. 2022, 83, 86–98. [Google Scholar]
  41. Lu, T.; Ma, R.; Dong, W.; Teng, K.Y.; Kollath, D.S.; Li, Z.; Yi, J.; Bustillos, C.; Ma, S.; Tian, L.; et al. Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19. Nat. Commun. 2022, 13, 2576. [Google Scholar] [CrossRef]
  42. Gang, M.; Marin, N.D.; Wong, P.; Neal, C.C.; Marsala, L.; Foster, M.; Schappe, T.; Meng, W.; Tran, J.; Schaettler, M.; et al. CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. Blood 2020, 136, 2308–2318. [Google Scholar] [CrossRef]
  43. Bonam, S.R.; Kaveri, S.V.; Sakuntabhai, A.; Gilardin, L.; Bayry, J. Adjunct immunotherapies for the management of severely ill COVID-19 patients. Cell Rep. Med. 2020, 1, 100016. [Google Scholar] [CrossRef]
  44. Spanholtz, J.; Tordoir, M.; Eissens, D.; Preijers, F.; van der Meer, A.; Joosten, I.; Schaap, N.; de Witte, T.M.; Dolstra, H. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy. PLoS ONE 2010, 5, e9221. [Google Scholar]
  45. Gleason, J.; Zhao, Y.; Raitman, I.; Kang, L.; He, S.; Hariri, R. Human placental hematopoietic stem cell derived natural killer cells (CYNK-001) mediate protection against influenza a viral infection. Hum. Vaccines Immunother. 2022, 18, 2055945. [Google Scholar] [CrossRef] [PubMed]
  46. Ding, Z.; Li, Q.; Zhang, R.; Xie, L.; Shu, Y.; Gao, S.; Wang, P.; Su, X.; Qin, Y.; Wang, Y.; et al. Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. Signal. Transduct. Target Ther. 2021, 6, 26. [Google Scholar]
  47. Wang, X.; Guan, F.; Miller, H.; Byazrova, M.G.; Cndotti, F.; Benlagha, K.; Camara, N.O.S.; Lei, J.; Filatov, A.; Liu, C. The role of dendritic cells in COVID-19 infection. Emerg. Microbes Infect. 2023, 12, 2195019. [Google Scholar]
  48. Winheim, E.; Rinke, L.; Lutz, K.; Reischer, A.; Leutbecher, A.; Wolfram, L.; Rausch, L.; Kranich, J.; Wratil, P.R.; Huber, J.E.; et al. Impaired function and delayed regeneration of dendritic cells in COVID-19. PLoS Pathog. 2021, 17, e1009742. [Google Scholar]
  49. Soilleux, E.J.; Morris, L.S.; Leslie, G.; Chehimi, J.; Luo, Q.; Levroney, E.; Trowsdale, J.; Montaner, L.J.; Doms, R.W.; Weissman, D.; et al. Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro. J. Leukoc. Biol. 2002, 71, 445–457. [Google Scholar] [CrossRef] [PubMed]
  50. Wang, K.; Chen, W.; Zhang, Z.; Deng, Y.; Lian, J.Q.; Du, P.; Wei, D.; Zhang, Y.; Sun, X.X.; Gong, L.; et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct. Target. Ther. 2020, 5, 283. [Google Scholar]
  51. Pérez-Gómez, A.; Vitallé, J.; Gasca-Capote, C.; Gutierrez-Valencia, A.; Trujillo-Rodriguez, M.; Serna-Gallego, A.; Muñoz-Muela, E.; Jiménez-Leon, M.L.R.; Rafii-El-Idrissi Benhnia, M.; Rivas-Jeremias, I.; et al. Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection. Cell Mol. Immunol. 2021, 18, 2128–2139. [Google Scholar]
  52. Park, A.; Iwasaki, A. Type I and Type III Interferons—Induction, Signaling, Evasion, and Application to Combat COVID-19. Cell Host Microbe 2020, 27, 870–878. [Google Scholar]
  53. Zhou, R.; To, K.K.; Wong, Y.C.; Liu, L.; Zhou, B.; Li, X.; Huang, H.; Mo, Y.; Luk, T.Y.; Lau, T.T.; et al. Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses. Immunity 2020, 53, 864–877. [Google Scholar] [CrossRef] [PubMed]
  54. Young Chung, J.; Thone, M.N.; Davies, J.E.; Gach, J.S.; Huw Davies, D.; Forthal, D.N.; Kwon, Y.J. Vaccination against SARS-CoV-2 using extracellular blebs derived from spike protein-expressing dendritic cells. Cell Immunol. 2023, 386, 104691. [Google Scholar] [CrossRef] [PubMed]
  55. Galati, D.; Zanotta, S.; Capitelli, L.; Bocchino, M. A bird’s eye view on the role of dendritic cells in SARS-CoV-2 infection: Perspectives for immune-based vaccines. Allergy 2022, 77, 100–110. [Google Scholar] [CrossRef]
  56. Maison, D.P.; Deng, Y.; Gerschenson, M. SARS-CoV-2 and the host-immune response. Front. Immunol. 2023, 14, 1195871. [Google Scholar]
  57. Merad, M.; Martin, J. Pathological inflammation in patients with COVID-19: A key role for monocytes and macrophages. Nat. Rev. Immunol. 2020, 20, 355–362. [Google Scholar] [CrossRef]
  58. Savan, R.; Gale, M., Jr. Innate immunity and interferon in SARS-CoV-2 infection outcome. Immunity 2023, 56, 1443–1450. [Google Scholar] [CrossRef]
  59. Lee, J.S.; Koh, J.Y.; Yi, K.; Kim, Y.I.; Park, S.J.; Kim, E.H.; Kim, S.M.; Park, S.H.; Ju, Y.S.; Choi, Y.K.; et al. Single-cell transcriptome of bronchoalveolar lavage fluid reveals sequential change of macrophages during SARS-CoV-2 infection in ferrets. Nat. Commun. 2021, 12, 4567. [Google Scholar]
  60. George, P.M.; Wells, A.U.; Jenkins, R.G. Pulmonary fibrosis and COVID-19: The potential role for antifibrotic therapy. Lancet Respir. Med. 2020, 8, 807–815. [Google Scholar]
  61. Henderson, N.C.; Rieder, F.; Wynn, T.A. Fibrosis: From mechanisms to medicines. Nature 2020, 587, 555–566. [Google Scholar]
  62. Ghahremani Piraghaj, M.; Soudi, S.; Ghanbarian, H.; Bolandi, Z.; Namaki, S.; Hashemi, S.M. Effect of efferocytosis of apoptotic mesenchymal stem cells (MSCs) on C57BL/6 peritoneal macrophages function. Life Sci. 2018, 212, 203–212. [Google Scholar] [CrossRef]
  63. Juárez-Navarro, K.J.; Padilla-Camberos, E.; Díaz, N.F.; Miranda-Altamirano, A.; Díaz-Martínez, N.E. Human mesenchymal stem cells: The present alternative for high-incidence diseases, even SARS-Cov-2. Stem Cells Int. 2020, 2020, 8892189. [Google Scholar] [CrossRef]
  64. Krasnodembskaya, A.; Samarani, G.; Song, Y.; Zhuo, H.; Su, X.; Lee, J.W.; Gupta, N.; Petrini, M.; Matthay, M.A. Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am. J. Physiol. Lung Cell. Mol. Physiol. 2012, 302, 1003–1013. [Google Scholar] [CrossRef] [PubMed]
  65. Ji, F.; Li, L.; Li, Z.; Jin, Y.; Liu, W. Mesenchymal stem cells as a potential treatment for critically ill patients with coronavirus disease. Stem Cells Transl. Med. 2020, 9, 813–814. [Google Scholar] [CrossRef]
  66. Atluri, S.; Manchikanti, L.; Hirsch, J.A. Expanded Umbilical Cord Mesenchymal Stem Cells (UCMSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use. Pain Physician 2020, 23, e71–e83. [Google Scholar] [PubMed]
  67. Shetty, A.K. Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)-Induced Pneumonia. Aging Dis. 2020, 11, 462–464. [Google Scholar] [CrossRef] [PubMed]
  68. Ranieri, V.M.; Rubenfeld, G.D.; Thompson, B.T.; Ferguson, N.D.; Caldwell, E.; Fan, E.; Camporota, L.; Slutsky, A.S. Acute respiratory distress syndrome: The Berlin defnition. JAMA 2012, 301, 2526–2533. [Google Scholar]
  69. Sadeghi, B.; Roshandel, E.; Pirsalehi, A.; Kazemi, S.; Sankanian, G.; Majidi, M.; Salimi, M.; Aghdami, N.; Sadrosadat, H.; Samadi Kochaksaraei, S.; et al. Conquering the cytokine storm in COVID-19–induced ARDS using placenta-derived decidua stromal cells. J. Cell Mol. Med. 2021, 25, 10554–10564. [Google Scholar] [CrossRef]
  70. Adas, G.; Cukurova, Z.; Yasar, K.K.; Yilmaz, R.; Isiksacan, N.; Kasapoglu, P.; Yesilbag, Z.; Koyuncu, I.D.; Karaoz, E. The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial. Cell Transplant. 2021, 30, 9636897211024942. [Google Scholar] [CrossRef]
  71. Dilogo, I.H.; Aditianingsih, D.; Sugiarto, A.; Burhan, E.; Damayanti, T.; Sitompul, P.A.; Mariana, N.; Antarianto, R.D.; Liem, I.K.; Kispa, T.; et al. Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: A randomized controlled trial. Stem Cells Transl. Med. 2021, 10, 1279–1287. [Google Scholar] [CrossRef]
  72. Lanzoni, G.; Linetsky, E.; Correa, D.; Messinger Cayetano, S.; Alvarez, R.A.; Kouroupis, D.; Alvarez Gil, A.; Poggioli, R.; Ruiz, P.; Marttos, A.C.; et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl. Med. 2021, 10, 660–673. [Google Scholar]
  73. Meng, F.; Xu, R.; Wang, S.; Xu, Z.; Zhang, C.; Li, Y.; Yang, T.; Shi, L.; Fu, J.; Jiang, T.; et al. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: A phase 1 clinical trial. Signal Transduct. Target Ther. 2020, 5, 172. [Google Scholar] [CrossRef] [PubMed]
  74. Shi, L.; Huang, H.; Lu, X.; Yan, X.; Jiang, X.; Xu, R.; Wang, S.; Zhang, C.; Yuan, X.; Xu, Z.; et al. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: A randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct. Target Ther. 2021, 6, 58. [Google Scholar]
  75. Shi, L.; Yuan, X.; Yao, W.; Wang, S.; Zhang, C.; Zhang, B.; Song, J.; Huang, L.; Xu, Z.; Fu, J.L.; et al. Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial. EBioMedicine 2022, 75, 103789. [Google Scholar] [CrossRef] [PubMed]
  76. Shu, L.; Niu, C.; Li, R.; Huang, T.; Wang, Y.; Huang, M.; Ji, N.; Zheng, Y.; Chen, X.; Shi, L.; et al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res. Ther. 2020, 11, 361. [Google Scholar] [CrossRef] [PubMed]
  77. Xu, X.; Jiang, W.; Chen, L.; Xu, Z.; Zhang, Q.; Zhu, M.; Ye, P.; Li, H.; Yu, L.; Zhou, X.; et al. Evaluation of the safety and effcacy of using human menstrual bloodderived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial. Clin. Transl. Med. 2021, 11, e297. [Google Scholar] [CrossRef] [PubMed]
  78. Muthu, S.; Jeyaraman, M.; Kotner, M.B.; Jeyaraman, N.; Rajendran, R.L.; Sharma, S.; Khanna, M.; Rajendran, S.N.S.; Oh, J.M.; Gangadaran, P.; et al. Evolution of Mesenchymal Stem Cell Therapy as an Advanced Therapeutic Medicinal Product (ATMP)—An Indian Perspective. Bioengineering 2022, 9, 111. [Google Scholar] [CrossRef]
  79. Pereira Chilima, T.D.; Moncaubeig, F.; Farid, F.F. Impact of allogeneic stem cell manufacturing decisions on cost of goods, process robustness and reimbursement. Biochem. Eng. J. 2018, 137, 132–151. [Google Scholar]
  80. Leng, Z.; Zhu, R.; Hou, W.; Feng, Y.; Yang, Y.; Han, Q.; Shan, G.; Meng, F.; Du, D.; Wang, S.; et al. Transplantation of ACE2-mesenchymal stem cells improve the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020, 11, 216–228. [Google Scholar] [CrossRef]
  81. Barkama, R.; Mayo, A.; Paz, A.; Solopov, A.; Mann, T.; Vadasz, Z.; Appel, T.; Ofir, R.; Shani, L.; Sheleg, M.; et al. Placenta-Derived Cell Therapy to Treat Patients with Respiratory Failure Due to Coronavirus Disease 2019. Crit. Care Explor. 2020, 2, e0207. [Google Scholar] [CrossRef]
  82. Yudintceva, N.; Mikhailova, N.; Fedorov, V.; Samochernych, K.; Vinogradova, T.; Muraviov, A.; Shevtsov, M. Mesenchymal Stem Cells and MSCs-Derived Extracellular Vesicles in Infectious Diseases: From Basic Research to Clinical Practice. Bioengineering 2022, 9, 662. [Google Scholar]
  83. Couto, P.S.; Al-Arawe, N.; Filgueiras, I.S.; Fonseca, D.L.M.; Hinterseher, I.; Catar, R.A.; Chinnadurai, R.; Bersenev, A.; Cabral-Marques, O.; Moll, G.; et al. Systematic review and meta-analysis of cell therapy for COVID-19: Global clinical trial landscape, published safety/efficacy outcomes, cell product manufacturing and clinical delivery. Front Immunol. 2023, 14, 1200180. [Google Scholar]
  84. Moll, G.; Drzeniek, N.; Kamhieh-Milz, J.; Geissler, S.; Volk, H.D.; Reinke, P. MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy. Front Immunol. 2020, 11, 1091. [Google Scholar]
  85. Cottle, C.; Porter, A.P.; Lipat, A.; Turner-Lyles, C.; Nguyen, J.; Moll, G.; Chinnadurai, R. Impact of Cryopreservation and Freeze-Thawing on Therapeutic Properties of Mesenchymal Stromal/Stem Cells and Other Common Cellular Therapeutics. Curr. Stem Cell Rep. 2022, 8, 72–92. [Google Scholar] [PubMed]
  86. Tripathi, H.; Domingues, A.; Donahue, R.; Cras, A.; Guerin, C.L.; Gao, E.; Levitan, B.; Ratajczak, M.Z.; Smadja, D.M.; Abdel-Latif, A.; et al. Combined Transplantation of Human MSCs and ECFCs Improves Cardiac Function and Decrease Cardiomyocyte Apoptosis After Acute Myocardial Infarction. Stem Cell Rev. Rep. 2023, 19, 573–577. [Google Scholar] [CrossRef]
Viruses 15 02148 g001
Figure 1. Three types of T cell therapies available for treating life-threatening viral infections. (a) SARS-CoV-2-specific T cells that specifically recognize the structural antigen membrane protein of SARS-CoV-2. (b). CAR-T cells specially designed to identify the viral antigen N protein of SARS-CoV-2. (c). Tregs play a key role in suppressing the activation, proliferation, and effector functions of other immune cells, thereby playing a protective role in inhibiting autoimmune inflammatory reactions in COVID-19 patients with excessive inflammation and cytokine storms.
Figure 1. Three types of T cell therapies available for treating life-threatening viral infections. (a) SARS-CoV-2-specific T cells that specifically recognize the structural antigen membrane protein of SARS-CoV-2. (b). CAR-T cells specially designed to identify the viral antigen N protein of SARS-CoV-2. (c). Tregs play a key role in suppressing the activation, proliferation, and effector functions of other immune cells, thereby playing a protective role in inhibiting autoimmune inflammatory reactions in COVID-19 patients with excessive inflammation and cytokine storms.
Viruses 15 02148 g001
Viruses 15 02148 g002
Figure 2. Different types of immune cell therapies for treating COVID-19.
Figure 2. Different types of immune cell therapies for treating COVID-19.
Viruses 15 02148 g002
Table 1. Immune-cell-based therapy clinical trials for COVID-19.
Table 1. Immune-cell-based therapy clinical trials for COVID-19.
StrategyStudy TitlePhaseNCT NumberStatus
Specific T cellSafety Infusion of Natural Killer cells or Memory T Cells as Adoptive Therapy in COVID-19 pneumonia or Lymphopenia1 and 2NCT04578210Completed
Generation of SARS-CoV-2-specific T Lymphocytes from Recovered Donors and Administration to High-risk COVID-19 Patients1 and 2NCT05447013Recruiting
Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients with Severe COVID-191NCT04351659Recruiting
Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients with Severe COVID-191 and 2NCT04457726Unknown
status
Viral Specific T Cell Therapy for COVID-19 Related Pneumonia1NCT04742595Recruiting
TregREgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia (RESOLVE)1NCT04468971Completed
RAPA-501-Allo Therapy of COVID-19-ARDS1 and 2NCT04482699Terminated
NLow Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19 (LILIADE-COVID)2NCT04357444Completed
Tregs for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 (regARDS)1NCT05027815Terminated
NK cellsA Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-191 and 2NCT04324996Unknown
status
Fase I Clinical Trial on NK Cells for COVID-191NCT04634370Unknown
status
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-191 and 2NCT04365101Active, not recruiting
Off-the-shelf NK Cells (KDS-1000) as Immunotherapy for COVID-191 and 2NCT04797975Withdrawn
NK Cells Treatment for COVID-191NCT04280224Recruiting
Dendritic cellsInjection and infusion of LV-SMENP DC vaccine and antigen-specific CTLs3NCT04276896Recruiting
Phase I-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults1 and 2NCT04386252Withdrawn
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years with a Pediatric Expansion in Adolescents (12 to <18 Years) at Risk for SARS-CoV-23NCT04611802Active, not recruiting
Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals3NCT04368728Completed
A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-193NCT04470427Completed
Dendritic Cell Vaccine to Prevent COVID-191NCT04685603Unknown
status
Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection1NCT04690387Completed
Phase I-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults1 and 2NCT04386252Withdrawn
Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected with COVID-192NCT05007496Completed
Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents (NH-Shingrix)1NCT04523246Active, not recruiting
MonocytesThe MONACO Cell Therapy Study: Monocytes as an Anti-fibrotic Treatment After COVID-19 (MONACO)1 and 2NCT04805086Unknown
status
Mesenchymal stem cellsMesenchymal Stem Cells Therapy in Patients With COVID-19 PneumoniaNot
applicable		NCT04713878Completed
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients (REPAIR)Not
applicable		NCT04898088Completed
NestaCell® Mesenchymal Stem Cell to Treat Patients with Severe COVID-19 Pneumonia (HOPE)2NCT04315987Completed
An Exploratory Study of ADR-001 in Patients with Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19)1NCT04522986Completed
Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients (DW-MSC)1NCT04535856Completed
Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)1 and 2NCT04345601Completed
Efficacy of Infusions of MSC from Wharton Jelly in the SARS-CoV-2 (COVID-19) Related Acute Respiratory Distress Syndrome (MSC-COVID19)2NCT04625738Completed
Mesenchymal Stem Cells for the Treatment of COVID-191NCT04573270Completed
A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs Against COVID-19.2NCT04348435Completed
A Clinical Trial to Determine the Safety and Efficacy of HB-adMSCs to Provide Protection Against COVID-192NCT04349631Completed
A First-In-Human Phase 1b Study of AmnioPul-02 in COVID-19/Other LRTI1NCT05348772Completed
Menstrual Blood Stem Cells in Severe Covid-191 and 2NCT05019287Completed
Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19)2NCT04288102Completed
Use of UC-MSCs for COVID-19 Patients1 and 2NCT04355728Completed
Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients with Severe Pneumonia Due to COVID-191 and 2NCT04366323Completed
Treatment of COVID-19 Associated Pneumonia with Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells1 and 2NCT04382547Completed
The MEseNchymal coviD-19 Trial: MSCs in Adults with Respiratory Failure Due to COVID-19 or Another Underlying Cause (MEND)1 and 2NCT04537351Completed
Clinical Use of Stem Cells for the Treatment of Covid-191 and 2NCT04392778Completed
Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients with Respiratory Distress Due to COVID-19 (COVIDMES)1 and 2NCT04390139Completed
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With COVID-19 (UMSC01)1 and 2NCT05501418Active, not recruiting
Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER) (RECOVER)1NCT04629105Active, not recruiting
Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19Early
phase 1		NCT04456361Active, not recruiting
Multiple Dosing of Mesenchymal Stromal Cells in Patients with ARDS (COVID-19)2NCT04466098Active, not recruiting
Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS (ULSC)1 and 2NCT04494386Active, not recruiting
Study of the Safety of Therapeutic Tx with Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation1NCT04397796Active, not recruiting
Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-192NCT04362189Terminated
Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory Distress2NCT04903327Terminated
hCT-MSCs for COVID19 ARDS1 and 2NCT04399889Terminated
MSCs in COVID-19 ARDS3NCT04371393Terminated
Mesenchymal Stem Cell Infusion for COVID-19 Infection2NCT04444271Unknown
status
Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19 (COVID-19)2NCT04416139Unknown
status
Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem CellsEarly
phase 1		NCT04302519Unknown
status
Safety and Efficacy of Mesenchymal Stem Cells in the Management of Severe COVID-19 Pneumonia (CELMA)2NCT04429763Unknown
status
Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019Early
phase 1		NCT04371601Unknown
status
Mesenchymal Stem Cells in Patients Diagnosed With COVID-191NCT04611256Unknown
status
Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients with Coronavirus Disease 2019 (COVID-19)1 and 2NCT04346368Unknown
status
Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically-Ill COVID-19 Patients1NCT04457609Unknown
status
Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-191NCT04252118Unknown
status
Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia1 and 2NCT04339660Unknown
status
Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome2 and 3NCT04366063Unknown
status
Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients1 and 2NCT04336254Unknown
status
Treatment of COVID-19 Patients Using Wharton’s Jelly-Mesenchymal Stem Cells1NCT04313322Unknown
status
Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19Not
applicable		NCT04273646Unknown
status
Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs1 and 2NCT04461925Unknown
status
Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in Indonesia2NCT04753476Unknown
status
A Study of Cell Therapy in COVID-19 Subjects with Acute Kidney Injury Who Are Receiving Renal Replacement Therapy1 and 2NCT04445220Unknown
status
A Study to Collect Bone Marrow for Process Development and Production of BM-MSC to Treat Severe COVID19 Pneumonitis (COMET20d)ObservationalNCT04397471Unknown
status
Safety and Efficacy of Intravenous Wharton’s Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 191 and 2NCT04390152Unknown
status
Umbilical Cord (UC)-Derived Mesenchymal Stem Cells (MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia2NCT04269525Unknown
status
Mesenchymal Stromal Cells for the Treatment of Patients With COVID-19.1 and 2NCT05433298Withdrawn
ASC Therapy for Patients with Severe Respiratory COVID-19 (ASC COVID-19)1 and 2NCT04341610Withdrawn
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 “Long Haul” Pulmonary Compromise2NCT04909892Withdrawn
Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory Distress2NCT04728698Withdrawn
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome2NCT04909879Withdrawn
Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19 (COVID-19)1NCT04490486Withdrawn
BAttLe Against COVID-19 Using MesenchYmal Stromal Cells2NCT04348461Suspended
A Study of ADR-001 in Patients with Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19)2NCT04888949Recruiting
A Clinical Study on Safety and Effectiveness of Mesenchymal Stem Cell Exosomes for the Treatment of COVID-19.Early
phase 1		NCT05787288Recruiting
Cord Blood-Derived Mesenchymal Stem Cells for the Treatment of COVID-19 Related Acute Respiratory Distress Syndrome1 and 2NCT04565665Recruiting
Application and Research of Mesenchymal Stem Cells in Alleviating Severe Development of COVID-19 Infection1 and 2NCT05741099Recruiting
UC-MSCs in the Treatment of Severe and Critical COVID-19 Patients3NCT05682586Recruiting
Allogenic UCMSCs as Adjuvant Therapy for Severe COVID-19 Patients (UCMSC)2 and 3NCT05132972Recruiting
A Phase II Study in Patients with Moderate to Severe ARDS Due to COVID-192NCT04780685Recruiting
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress2NCT04905836Recruiting
Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome (HBPCOVID02)2NCT05126563Recruiting
Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia1 and 2NCT04527224Recruiting
Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Exosomes in Treating Chronic Cough After COVID-19Early
phase 1		NCT05808400Recruiting
UC-MSCs in the Treatment of Severe and Critical COVID-19 Patients with Refractory Hypoxia3NCT05689008Recruiting
Study of Descartes-30 in Acute Respiratory Distress Syndrome1 and 2NCT04524962Recruiting
Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions1 and 2NCT04684602Recruiting
Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) (REALIST1 and 2NCT03042143Recruiting
Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-192NCT04428801Not yet
recruiting
Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias (SAMPSON-1)1NCT05286255Not yet
recruiting
Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs)2NCT05017298Not yet
recruiting
Treatment of Long COVID Symptoms Utilizing Autologous Stem Cells Following COVID-19 Infection1NCT05669261Not yet
recruiting
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 “Long Haul” Pulmonary Compromise (BR)2NCT04992247Not yet
recruiting
Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Long COVID-192NCT05719012Not yet
recruiting
Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS)2NCT04377334Not yet
recruiting
Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS1 and 2NCT04452097Not yet
recruiting
AllogeneiC Expanded Human MSC Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial (ACE_CARD)1NCT05491681Not yet
recruiting
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Wang, Y.; Liang, Q.; Chen, F.; Zheng, J.; Chen, Y.; Chen, Z.; Li, R.; Li, X. Immune-Cell-Based Therapy for COVID-19: Current Status. Viruses 2023, 15, 2148. https://doi.org/10.3390/v15112148

AMA Style

Wang Y, Liang Q, Chen F, Zheng J, Chen Y, Chen Z, Li R, Li X. Immune-Cell-Based Therapy for COVID-19: Current Status. Viruses. 2023; 15(11):2148. https://doi.org/10.3390/v15112148

Chicago/Turabian Style

Wang, Yiyuan, Qinghe Liang, Fengsheng Chen, Jiehuang Zheng, Yan Chen, Ziye Chen, Ruopeng Li, and Xiaojuan Li. 2023. "Immune-Cell-Based Therapy for COVID-19: Current Status" Viruses 15, no. 11: 2148. https://doi.org/10.3390/v15112148

APA Style

Wang, Y., Liang, Q., Chen, F., Zheng, J., Chen, Y., Chen, Z., Li, R., & Li, X. (2023). Immune-Cell-Based Therapy for COVID-19: Current Status. Viruses, 15(11), 2148. https://doi.org/10.3390/v15112148

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop